Recommended by Valerie Kramer this week on CNBC.
Listened to the presentation outlining progress that this company has made to get its product "Provenge" to the market. Reviewed the yahoo message board on this stock.
Noted that it has a $4 Billion market capitalization. Considered selling Biogen-Ideac and buying DNDN.
Immunotherapy looks promising for tumors resistant to more traditional therapy
No comments:
Post a Comment